People · Operator
Named in public records as an officer, director or promoter · active 2011–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $612.3M | 2014 |
| Yaupon Therapeutics Inc | — | Pharmaceuticals | Series A | $21.6M | $256.8M | 2011 |
| Ralexar Therapeutics, Inc. | — | Pharmaceuticals | Series A | $19.0M | $132.5M | 2014 |
Kamil Ali-Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kamil Ali-Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Tullman | 3 | 7 |
| Albert Cha | 2 | 9 |
| Neal Walker | 2 | 5 |
| Douglas Gessl | 2 | 4 |
| Somu Subramaniam | 1 | 17 |
| Ketan Patel | 1 | 10 |
| David Gordon | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| James Huang | 1 | 5 |
| Andrew Schiff | 1 | 5 |
| Somasundaram Subramaniam | 1 | 5 |
| Jason Hong | 1 | 4 |
| Raju Mohan | 1 | 4 |
| Maxine Gowen | 1 | 4 |
| Christopher Powala | 1 | 3 |
| Joseph Monahan | 1 | 3 |
| Andrew A. Schiff | 1 | 3 |
| Andrew Powell | 1 | 3 |
| Greg Vontz | 1 | 3 |
| William A. Humphries | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.